Product Information
TAZAROTENE 0.05% CREAM is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $6.8890 per GM under NDC 45802070694. Its NADAC has been published 94 times since Dec 18, 2024.
FDA first approved this application on Jul 15, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802070694
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
TAZAROTENEApproval Type
Generic (ANDA)
FDA Application
ANDA217075FDA Approved
7/15/2024
TE Code
AB
On Market Since
9/9/2024
Pharmacological Classes
Price Statistics
The NADAC for TAZAROTENE 0.05% CREAM has been published 94 times since Dec 18, 2024, and over the history we have for it it has declined 33.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.8890 per GM |
|---|---|
| All-time high | $10.7939 (May 14, 2025) |
| All-time low | $6.5803 (Jul 22, 2026) |
| 52-week high | $9.2719 |
| 52-week low | $6.5803 |
| Median price | $8.4991 |
| Average price | $8.7769 |
| Largest weekly change | -8.3% (Oct 22, 2025) |
| Weeks tracked | 94 |
| Tracking since | Dec 18, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the tazarotene market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tazarotene market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Retinoid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TAZAROTENE 0.05% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for TAZAROTENE 0.05% CREAM, manufactured by Padagis Israel Pharmaceuticals Ltd, is $6.8890 per GM (NDC 45802070694), effective Sep 30, 2026.
How has the price of TAZAROTENE 0.05% CREAM changed over time?
Over the history we have for it, the NADAC for TAZAROTENE 0.05% CREAM has declined 33.4%. It has been tracked across 94 weekly CMS publications since Dec 18, 2024.
What are the highest and lowest recorded NADAC prices for TAZAROTENE 0.05% CREAM?
Since Dec 18, 2024, the NADAC for TAZAROTENE 0.05% CREAM has ranged from a low of $6.5803 (Jul 22, 2026) to a high of $10.7939 (May 14, 2025), with a median of $8.4991 per GM.
Are there cheaper alternatives to TAZAROTENE 0.05% CREAM?
No other NADAC-published product currently shares the active ingredient and strength of TAZAROTENE 0.05% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TAZAROTENE 0.05% CREAM?
TAZAROTENE 0.05% CREAM (NDC 45802070694) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.